Photo from wikipedia
Ophthalmologists increasingly depend on new drugs to advance their treatment options. These options are limited by restraints on reimbursements for new and expensive drugs. These restraints are put in place… Click to show full abstract
Ophthalmologists increasingly depend on new drugs to advance their treatment options. These options are limited by restraints on reimbursements for new and expensive drugs. These restraints are put in place through health policy decisions based on cost‐effectiveness analyses (CEA). Cost‐effectiveness analyses need to be valid and of good quality to support correct decisions to create new treatment opportunities. In this study, we report the quality, validity and usefulness of CEAs for therapies for nAMD.
Keywords:
quality validity;
validity usefulness;
cost effectiveness;
cost
Journal Title: Acta Ophthalmologica
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Acta Ophthalmologica
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!